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Low vascular resistance after cardiopulmonary bypassoccurs fairly frequently.1,3 In the early postoperativephase after heart transplantation, decrease of blood pres-sure might be aggravated by the effects of antigen release
from the donor organ and acute inflammatory response. Decrease
of systemic resistance in patients after cardiac transplantation may
lead to significant organ hypoperfusion and is usually treated with
vasoconstrictors. We report a case of a patient early after heart
transplantation in a severe hyperdynamic state, including high car-
diac output and low vascular resistance, who was successfully
treated with a single dose of methylene blue.
Clinical Summary
A 55-year-old man with congestive heart failure (cardiac index, 1.8
L · min–1 · m–2) with an automatic implantable cardioverter defi-
brillator device underwent orthotopic bicaval cardiac transplanta-
tion and explantation of the automatic implantable cardioverter
defibrillator device. The underlying disease was a dilative car-
diomyopathy with a history of myocarditis. Preoperative evalua-
tion revealed impaired left ventricular systolic function (ejection
fraction, 20%) and moderate pulmonary hypertension (mean pul-
monary artery pressure, 28 mm Hg). The patient was on a program
of furosemide, spironolactone, amiodarone, metoprolol, captopril,
and digitoxin preoperatively. His clinical status reached New York
Heart Association class IV. Blood pressure was 100/60 mm Hg
preoperatively.
Cold ischemia time was 158 minutes, and aortic clamp time
was 31 minutes. The patient was separated from cardiopulmonary
bypass without problems after a reperfusion time of 60 minutes.
Thereafter, his blood pressure progressively sagged. The central
venous pressure was 10 mm Hg, and the hemoglobin level was 8.1
g/dL. Blood loss was negligible, and oxygen tension was 375 mm
Hg on an inspired oxygen fraction of 1.0 at transfer to the intensive
care unit. Online hemodynamic monitoring revealed a cardiac out-
put of 11.2 L/min and a systemic vascular resistance of 480 dynes
·s–1 · cm–5 under norepinephrine infusion at a rate of 0.37 µg · kg–1
· min–1. Over the course of 4 hours, the requirement for norepi-
nephrine to maintain a systolic blood pressure above 100 mm Hg
escalated to 1 µg · kg–1 · min–1. Methylene blue was given intra-
venously (2 mg/kg body weight) over 30 minutes, resulting in an
immediate rise in blood pressure. One hour after administration,
norepinephrine requirements decreased to 0.22 µg · kg–1 · min–1,
and 6 hours later, norepinephrine could be discontinued. Figure 1
demonstrates the norepinephrine requirements over time, together
with pulmonary artery pressure, mean arterial pressure, and central
venous pressure recordings. No additional methylene blue was
necessary, and minimal intravenous doses of epinephrine were
administered after the second postoperative day, according to our
regular strategy after heart transplantation.
Hemodynamic status remained stable over the next days. Fever
did not occur, and no signs of an inflammatory response, such as
high leukocyte counts and C-reactive protein, could be document-
ed. Creatine kinase levels peaked at 673 IU after 60 hours and cre-
atine kinase MB levels peaked at 53 IU after 2 hours postopera-
tively and decreased gradually. Immunosuppression was started 6
hours after procedure with antithymocyte globulin (100 mg),
which was administered daily for 3 consecutive days.
Cyclosporine (INN: ciclosporin) was started on day 3 after trans-
plant because of an initial increase of creatinine and urea serum
levels. Urine was discolored, but its quantity was normal.
Postoperative nonoliguric renal dysfunction persisted until day 10
after transplantation and resolved with medical treatment. Further
laboratory findings, including pancreatic enzyme levels, blood cell
counts, and coagulation factors remained within normal postoper-
ative ranges. The first postoperative biopsy specimen was free of
rejection. Cyclosporine blood levels were responsive on usual dose
modifications. We do not have a reason to suspect any drug inter-
action of methylene blue with any of the usually administered
post-transplantation medications. The patients’ clinical condition
is excellent 2 months after transplantation.
Discussion
Decrease of vascular tone after cardiac transplantation is believed
to occur because of (1) general inflammatory response to car-
diopulmonary bypass1 and (2) release of antigens from graft tissue,
which activate host immune mechanisms that become operative in
the early reperfusion phase.1,3 An adequate blood pressure, how-
ever, is required for sufficient organ perfusion and undisturbed
graft function during the early postoperative time. Vasoplegia at
this stage can be severe and refractory to conservative therapy and
fluid administration. After orthotopic heart transplantation, loss of
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peripheral vascular resistance may become life-threatening with
respect to the limitations of right-sided heart function. The under-
lying mechanism is believed to be increased nitric oxide synthesis,
which in turn stimulates guanylate cyclase and activates the pro-
duction of cyclic guanosine 3´,5´ monophosphate (cGMP), result-
ing in vascular relaxation.4 Methylene blue inhibits guanylate
cyclase, avoiding the cGMP-dependent vasorelaxant effect of
nitric oxide in the smooth muscle of the vessels. Myles and col-
leagues4 failed to identify an increase in nitric oxide release after
CPB by means of analysis of urine nitrite-nitrate levels. Evora and
colleagues2 speculate on the existence of a distinct, nonnitric,
cGMP-dependent pathway with different receptors, different G
proteins, or both, or else a sensitization of vascular smooth muscle
cells to the action of nitric oxide, as hypothesized by Yiu and col-
leagues.3 On the basis of this theoretic background, methylene
blue has also been administered to treat sepsis and anaphylactic
shock.2,5
To our knowledge, we report the first experience of vasoplegia
treatment with methylene blue after heart transplantation and
believe that this drug deserves our attention because of its cate-
cholamine-saving effect, thus preventing possible malperfusion.
The postoperative course of our patient after orthotopic heart trans-
plantation did not differ from others in which methylene blue was
not used, except from the impressive shortening of norepinephrine
administration, volume saving, and decrease of monitoring
requirements in the intensive care unit. We did not identify any
adverse drug interactions with immunosuppressive drugs or signif-
icant organ malfunction. Further studies are necessary to identify
possible mechanisms and side effects of the use of methylene blue
after cardiac operations.
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Figure 1. Administration of methylene blue results in an immediate fall of norepinephrine requirements and a con-
sequent rise of blood pressure. Mean pulmonary artery pressure curve descends parallel to withdrawal of nor-
epinephrine.
